venBio Partners L.P. 13F Holdings · last filed Q4 2018
venBio Partners L.P. reported 2 securities worth $38.08M in its SEC 13F filing for Q4 2018 (period ended 2018-12-31). Top holdings: VRNA (22.18%), VYNE (15.82%).
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | Apellis Pharmaceuticals, Inc | $23.6M | 62.01% | 1.8M | Hold | |
| 2 | VRNA | Verona Pharma PLC | $8.4M | 22.18% | 875,000 | Hold |
| 3 | VYNE | Menlo Therapeutics Inc. | $6.0M | 15.82% | 1.5M | Hold |
Source: SEC Form 13F filings · as of 2018-12-31
Every position in this 13F-HR, with its change from the prior quarter.
13F holdings, latest quarter
SourceSEC EDGAR13F-HR